Literature DB >> 20116820

A varicella-zoster virus mutant impaired for latency in rodents, but not impaired for replication in cell culture.

Aruna P N Ambagala1, Tammy Krogmann, Jing Qin, Lesley Pesnicak, Jeffrey I Cohen.   

Abstract

While trying to generate a site-directed deletion in the ORF63 latency-associated gene of varicella-zoster virus (VZV) Oka, we constructed a virus with an unexpected rearrangement. The virus has a small deletion in both copies of ORF63 and two copies of a cassette inserted between ORFs 64/65 and 68/69 containing (a) truncated ORF62, (b) ORF63 with a small deletion, and (c) full-length ORF64. The virus was not impaired for growth in human cells, induced higher levels of neutralizing antibodies in guinea pigs, and was impaired for latency in cotton rats compared with parental virus (p=0.0022). Additional mutants containing the same truncation in ORF62, with or without the ORF63 deletion, were less impaired for latency. A VZV Oka mutant, replicating to similar titers and inducing a comparable immune response as parental virus, but impaired for latency, might serve as a safer vaccine and be less likely to reactivate to cause zoster. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20116820      PMCID: PMC3398405          DOI: 10.1016/j.virol.2010.01.007

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Varicella vaccine revisited.

Authors:  P LaRussa; S P Steinberg; E Shapiro; M Vazquez; A A Gershon
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

2.  Varicella vaccine revisited.

Authors:  J Seward; A Jumaan; S Schmid
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

3.  Varicella-zoster virus gene expression in latently infected and explanted human ganglia.

Authors:  P G Kennedy; E Grinfeld; J E Bell
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR.

Authors:  R J Cohrs; J Randall; J Smith; D H Gilden; C Dabrowski; H van Der Keyl; R Tal-Singer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children.

Authors:  P R Krause; D M Klinman
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

6.  Varicella-zoster virus open reading frame 2 encodes a membrane phosphoprotein that is dispensable for viral replication and for establishment of latency.

Authors:  Hitoshi Sato; Lesley Pesnicak; Jeffrey I Cohen
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Physical interaction between two varicella zoster virus gene regulatory proteins, IE4 and IE62.

Authors:  M L Spengler; W T Ruyechan; J Hay
Journal:  Virology       Date:  2000-07-05       Impact factor: 3.616

8.  Nuclear accumulation of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, is inhibited by phosphorylation mediated by the VZV open reading frame 66 protein kinase.

Authors:  P R Kinchington; K Fite; S E Turse
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

9.  The postmarketing safety profile of varicella vaccine.

Authors:  R G Sharrar; P LaRussa; S A Galea; S P Steinberg; A R Sweet; R M Keatley; M E Wells; W P Stephenson; A A Gershon
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

10.  Genome-wide reduction in transcriptomal profiles of varicella-zoster virus vaccine strains compared with parental Oka strain using long oligonucleotide microarrays.

Authors:  Esther Grinfeld; Alan Ross; Thorsten Forster; Peter Ghazal; Peter G E Kennedy
Journal:  Virus Genes       Date:  2008-11-27       Impact factor: 2.332

View more
  7 in total

1.  Differentiated neuroblastoma cells provide a highly efficient model for studies of productive varicella-zoster virus infection of neuronal cells.

Authors:  Jenna Christensen; Megan Steain; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  A sequence within the varicella-zoster virus (VZV) OriS is a negative regulator of DNA replication and is bound by a protein complex containing the VZV ORF29 protein.

Authors:  Mohamed I Khalil; Ann Arvin; Jeremy Jones; William T Ruyechan
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

3.  Varicella zoster virus latency.

Authors:  Emily Eshleman; Aamir Shahzad; Randall J Cohrs
Journal:  Future Virol       Date:  2011-03       Impact factor: 1.831

Review 4.  Modeling Varicella Zoster Virus Persistence and Reactivation - Closer to Resolving a Perplexing Persistent State.

Authors:  Lillian Laemmle; Ronald S Goldstein; Paul R Kinchington
Journal:  Front Microbiol       Date:  2019-07-24       Impact factor: 5.640

Review 5.  Current In Vivo Models of Varicella-Zoster Virus Neurotropism.

Authors:  Ravi Mahalingam; Anne Gershon; Michael Gershon; Jeffrey I Cohen; Ann Arvin; Leigh Zerboni; Hua Zhu; Wayne Gray; Ilhem Messaoudi; Vicki Traina-Dorge
Journal:  Viruses       Date:  2019-05-31       Impact factor: 5.048

6.  Antiviral Targeting of Varicella Zoster Virus Replication and Neuronal Reactivation Using CRISPR/Cas9 Cleavage of the Duplicated Open Reading Frames 62/71.

Authors:  Betty W Wu; Michael B Yee; Ronald S Goldstein; Paul R Kinchington
Journal:  Viruses       Date:  2022-02-12       Impact factor: 5.818

7.  Infected peripheral blood mononuclear cells transmit latent varicella zoster virus infection to the guinea pig enteric nervous system.

Authors:  Lin Gan; Mingli Wang; Jason J Chen; Michael D Gershon; Anne A Gershon
Journal:  J Neurovirol       Date:  2014-06-26       Impact factor: 3.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.